首页> 外文期刊>Journal of Radiation Research: Official Organ of the Japan Radiation Research Society >Radioprotective effect of newly synthesized toll-like receptor 5 agonist, KMRC011, in mice exposed to total-body irradiation
【24h】

Radioprotective effect of newly synthesized toll-like receptor 5 agonist, KMRC011, in mice exposed to total-body irradiation

机译:新合成的Toll样受体5激动剂,KMRC011的辐射防护作用,小鼠暴露于全身照射

获取原文
获取原文并翻译 | 示例
           

摘要

Exposure to ionizing radiation leads to severe damages in radiosensitive organs and induces acute radiation syndrome, including effects on the hematopoietic system and gastrointestinal system. In this study, the radioprotective ability of KMRC011, a novel toll-like receptor 5 (TLR5) agonist, was investigated in C57BL6/N mice exposed to lethal total-body gamma-irradiation. In a 30-day survival study, KMRC011-treated mice had a significantly improved survival rate compared with control after 11 Gy total-body irradiation (TBI), and it was found that the radioprotective activity of KMRC011 depended on its dosage and repeated treatment. In a 5-day short-term study, we demonstrated that KMRC011 treatment stimulated cell proliferation and had an anti-apoptotic effect. Furthermore, KMRC011 increased the expressions of genes related to DNA repair, such as Rad21, Gadd45b, Sod2 and Irg1, in the small intestine of lethally irradiated mice. Interestingly, downregulation of NF-kappa B p65 in the mouse intestine by KMRC011 treatment was observed. This data indicated that KMRC011 exerted a radioprotective activity partially by regulating NF-kappa B signaling. Finally, peak expression levels of G-CSF, IL-6, IFN-gamma, TNF-alpha and IP-10 induced by KMRC011 treatment were different depending on the route of administration and type of cytokine. These cytokines could be used as candidate biomarkers for the evaluation of KMRC011 clinical efficacy. Our data indicated that KMRC011 has radioprotective activity in lethally irradiated mice and may be developed as a therapeutic agent for radioprotection.
机译:暴露于电离辐射导致放射筛器官的严重损伤,并诱导急性辐射综合征,包括对造血系统和胃肠系统的影响。在该研究中,在暴露于致命总体γ-辐射的C57BL6 / N小鼠中研究了KMRC011,新型收费受体5(TLR5)激动剂的辐射防护能力。在30天的存活研究中,KMRC011治疗的小鼠的存活率显着提高,与对照在11GY的全身照射(TBI)后的对照相比,并且发现KMRC011的放射性保护活性取决于其剂量和重复处理。在5天的短期研究中,我们证明KMRC011治疗刺激细胞增殖并具有抗凋亡效应。此外,KMRC011增加了与DNA修复相关的基因的表达,例如RAD21,GADD45B,SOD2和IRG1,在苦难辐照小鼠的小肠中。有趣的是,通过KMRC011治疗观察到小鼠肠中NF-Kappa B P65的下调。该数据表明,KMRC011通过调节NF-Kappa B信号部分地施加辐射防护活性。最后,通过KMRC011治疗诱导的G-CSF,IL-6,IFN-Gamma,TNF-α和IP-10的峰表达水平取决于给药途径和细胞因子的类型。这些细胞因子可用作候选生物标志物,用于评估KMRC011临床疗效。我们的数据表明,KMRC011在致命的辐照小鼠中具有辐射防护活性,并且可以作为辐射保护的治疗剂开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号